LKA 651

Drug Profile

LKA 651

Alternative Names: LKA651

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Developer Alcon; Novartis
  • Class Eye disorder therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 15 Feb 2018 Novartis Pharmaceuticals completes a phase I trial in Diabetic macular oedema, Retinal vein occlusion and Wet age-related macular degeneration in USA and Puerto Rico (Intravitreous) (NCT02867735)
  • 07 Sep 2016 Novartis plans a phase I trial for Diabetic macular oedema, Retinal vein occlusion and Wet age-related macular degeneration in USA (NCT02867735)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top